Prostate Cancer Clinical Trials in Detroit, Michigan

9 studies are recruiting for prostate cancer in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford Hospital ( Site 0035), Detroit, Michigan

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

   To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Wayne State University, Detroit, Michigan

   Locations

   23 in total

   Run by

   Axonics, Inc.

   See if you can join NCT06511141 on ClinicalTrials.gov

4. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

   The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   95 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06855277 on ClinicalTrials.gov

5. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

   This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   19 in total

   Run by

   Pathos AI, Inc.

   See if you can join NCT06785636 on ClinicalTrials.gov

6. Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer

   This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an ed…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Henry Ford Cancer Pavilion, Detroit, Michigan

   Run by

   Henry Ford Health System

   See if you can join NCT05958082 on ClinicalTrials.gov

7. Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

   The goal of this clinical trial is to culturally adapt an educational genetic counseling intervention to increase the uptake in genetic counseling and testing among African Americans at risk for heredity cancers. With the help of community stakeholders and clinical genetic professionals the investi…

   Stage

   Not phased

   Ages

   20 to 79

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Run by

   Barbara Ann Karmanos Cancer Institute

   See if you can join NCT07436078 on ClinicalTrials.gov

8. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

   Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   121 in total

   Run by

   Prostate Cancer Clinical Trials Consortium

   See if you can join NCT03151629 on ClinicalTrials.gov

9. Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

   This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

   Locations

   13 in total

   Run by

   Celcuity Inc

   See if you can join NCT06190899 on ClinicalTrials.gov